SCHEMBL1721723

SCHEMBL1721723

O=C(O)C1Cc2c(Br)cccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
GID4 Q8IVV7 1/20 0.39
HDAC4 P56524 1/20 0.38
KDM4E B2RXH2 1/20 0.38
EDNRA P25101 4/20 0.36
EDNRB P24530 3/20 0.36
CYP1A2 P05177 1/20 0.35
PIM1 P11309 1/20 0.33
CSNK1A1 P48729 1/20 0.33
CDK5 Q00535 1/20 0.33
ROCK1 Q13464 1/20 0.33
DYRK1A Q13627 1/20 0.33
LRRK2 Q5S007 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
FABP5 Q01469 1/20 0.33
KIF11 P52732 1/20 0.33
BRD4 O60885 1/20 0.33
IDO1 P14902 1/20 0.32
PDE5A O76074 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19839756 0.82 GID4 (0.44) ALDH1A1GID4HDAC4CYP1A2FABP5
SCHEMBL4250760 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EPOLB
SCHEMBL1721640 0.79 ALDH1A1 (0.38) ALDH1A1EDNRAEDNRBCYP1A2
SCHEMBL8065941 0.78 ALDH1A1 (0.44) ALDH1A1HDAC4KDM4EEDNRAEDNRB
SCHEMBL9465746 0.78 ALDH1A1 (0.44) ALDH1A1HDAC4KIF11POLB
SCHEMBL1721952 0.78 TRPM5 (0.44) ALDH1A1
SCHEMBL29134428 0.76 EDNRA (0.41) ALDH1A1GID4HDAC4KDM4EEDNRA
SCHEMBL3031059 0.74 RBP4 (0.42) ALDH1A1
SCHEMBL15321486 0.73 MAOA (0.33) ALDH1A1GID4HDAC4KDM4EEDNRA
SCHEMBL20480557 0.71 HTR1A (0.38) ALDH1A1HDAC4POLBCASP6CTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729274-B2 Tricyclic heterocyclic derivatives MERCK SHARP & DOHME B.V. (NL) 2014-05-20 US disclosed
US-8729274-B2 Tricyclic heterocyclic derivatives MERCK SHARP & DOHME B.V. (NL) 2014-05-20 US disclosed
US-8729274-B2 Tricyclic heterocyclic derivatives MERCK SHARP & DOHME B.V. (NL) 2014-05-20 US disclosed
US-20120232122-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-09-13 US disclosed
US-20120232122-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-09-13 US disclosed
US-20120232122-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-09-13 US disclosed
EP-2406217-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES MSD Oss B.V. (NL) 2012-01-18 EP disclosed
US-8076325-B2 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-12-13 US disclosed
WO-2010103001-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2010-09-16 WO disclosed
WO-2010103001-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2010-09-16 WO disclosed
US-20100210680-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON 2010-08-19 US disclosed
US-20100210680-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON 2010-08-19 US disclosed
US-20100210680-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON 2010-08-19 US disclosed
EP-2203454-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. Organon (NL) 2010-07-07 EP disclosed
WO-2009037220-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2009-03-26 WO disclosed
WO-2009037220-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2009-03-26 WO disclosed
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210680-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES TPH1, HTR2C, TPH2 ALDH1A1 566/4885GID4 472/4885HDAC4 958/4885
US-20090069296-A1 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them OXER1, NR1H3, OXSR1 ALDH1A1 1056/4885GID4 2892/4885HDAC4 684/4885
US-20120232122-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES TPH1, HTR3C, TPH2 ALDH1A1 448/4885GID4 943/4885HDAC4 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.